Biotech Values

[hirogen]

EXEL -

I believe these remarks would contradict an OBF boundary which we know will spend at least 20-30% power (at an alpha of 0.013ish), leaving only 60-70% power instead of 90% for the final analysis.

The SA transcription is a little mangled, but the CMO also used the phrase "a very commonly used [alpha] spending function". Combine this with the fact all the recently approved drugs in mCRPC space used OBF in their pivotal trials and the co used OBF in their MTC trial, and I think it's highly likely COMET is using the same. The "vast majority" comment on final alpha could simply be the ~.046 allocated under OBF boundary vs .05, without explaining interim + final alphas aren't additive.